Skip to main content

Advertisement

Table 2 Primary analysis, baseline covariates after matching

From: Testosterone replacement therapy and the risk of adverse cardiovascular outcomes and mortality

Matching Variable Comparison Group (No TRTa) N = 210 Treatment Group (TRTa) N = 165 P-value Standardized Mean Difference
Median First Testosterone, ng/dL (IQR) 173 (146, 198) 179 (153, 203) 0.397 0.265
Median Second Testosterone, ng/dL (IQR) 170 (142, 198) 172 (138, 193) 0.798 0.085
Median Income, United States Dollars (IQR) 54,468 (47,300, 69,769) 59,311 (45,124, 70,631) 0.612 0.440
Median Age, years (IQR) 55 (49, 61.7) 55 (49, 62) 0.815 0.033
Diabetes (N, %) 88 (41.9%) 67 (40.6%) 0.800 0.026
Tobacco Use (N, %) 1 (0.5%) 1 (0.6%) 0.864 0.018
LDL > 130 mg/dL 18 (8.6%) 20 (12.2%) 0.258 0.117
Median LDL, mg/dL (IQR) 92 (73, 114) 91 (68, 113) 0.458 0.058
Hypertension (N, %) 142 (67.6%) 111 (67.3%) 0.943 0.007
Statin (N, %) 106 (50.5%) 86 (52.1%) 0.752 0.033
BMI ≥ 30 kg/m2 192 (91.9%) 144 (87.3%) 0.191 0.135
Median BMI, kg/m2 (IQR) 36.3 (32.1, 40.8) 35.6 (32.1, 40.1) 0.290 0.291
Previous Cardiovascular Disease (N, %) 36 (17.1%) 33 (20.0%) 0.478 0.074
Charlson Comorbidity Index (N, %)    0.532 0.117
0 86 (41%) 61 (37%)   
1 46 (21.9%) 44 (26.7%)   
> 1 78 (37.1%) 60 (36.3%)   
Composite Outcome (N, %) 16 (7.6%) 12 (7.3%)   
Myocardial Infarction (N, %) 3 (1.4%) 4 (2.4%)   
Stroke (N, %) 10 (4.8%) 6 (3.6%)   
Death (N, %) 3 (1.4%) 2 (1.2%)   
  1. aTRT: Testosterone Replacement Therapy
  2. IQR: Interquartile range
  3. LDL: Low-density lipoproteins
  4. BMI: Body mass index
  5. Patients were matched by age, median income, diabetes, tobacco, hypertension, LDL, stain, aspirin, body mass index (BMI), previous cardiovascular disease (previous acute myocardial infarction or acute cerebrovascular accident, or cerebrovascular or cardiovascular disease), and Charlson Comorbidity Index. Median matched exposure time was 1 month (IQR: 0, 4), max 78 months
  6. A patient treated with TRT with X months of exposure time between baseline and the initiation of treatment was matched to a comparison group patient (no TRT) that had more than X months of follow up since baseline. This period of time (X months) is the matched exposure time